EGFR and non-small cell lung carcinoma: This study suggests that NSCLC patients with both high TS expression and EGFR‐driving mutations might benefit more from a combination strategy of EGFR‐TKI and pemetrexed‐based chemotherapy than EGFR‐TKI monotherapy, which has profound clinical implications and therapeutic value.